ArticleBMC musculoskeletal disorders2021

Topical co-administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment.

Hideki Ueyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.